| Literature DB >> 31363906 |
Alexandre Chan1,2, Daniel L Hertz3, Manuel Morales4, Elizabeth J Adams5, Sharon Gordon6,7, Chia Jie Tan1,2, Nathan P Staff8, Jayesh Kamath9, Jeong Oh10, Shivani Shinde11,12, Doreen Pon13, Niharkia Dixit14,15, James D'Olimpio16,17, Cristina Dumitrescu18, Margherita Gobbo19, Kord Kober14,20, Samantha Mayo21, Linda Pang10, Ishwaria Subbiah10, Andreas S Beutler8, Katherine B Peters22, Charles Loprinzi8, Maryam B Lustberg23.
Abstract
Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating condition associated with a number of chemotherapeutic agents. Drugs commonly implicated in the development of CIPN include platinum agents, taxanes, vinca alkaloids, bortezomib, and thalidomide analogues. As a drug response can vary between individuals, it is hypothesized that an individual's specific genetic variants could impact the regulation of genes involved in drug pharmacokinetics, ion channel functioning, neurotoxicity, and DNA repair, which in turn affect CIPN development and severity. Variations of other molecular markers may also affect the incidence and severity of CIPN. Hence, the objective of this review was to summarize the known biological (molecular and genomic) predictors of CIPN and discuss the means to facilitate progress in this field.Entities:
Keywords: CIPN; Chemotherapy-induced peripheral neuropathy; Neuropathy
Mesh：
Substances：
Year: 2019 PMID： 31363906 PMCID： PMC6728179 DOI： 10.1007/s00520-019-04987-8
Source DB: PubMed Journal: Support Care Cancer ISSN： 0941-4355 Impact factor: 3.603